Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02250014
Other study ID # 14-0071.cc
Secondary ID 14-0071
Status Completed
Phase Phase 1
First received
Last updated
Start date October 5, 2015
Est. completion date December 21, 2020

Study information

Verified date February 2022
Source University of Colorado, Denver
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomized pilot phase I trial studies how well sargramostim after cryotherapy works in treating patients with prostate cancer. Biological therapies, such as sargramostim, use substances made from living organisms that may stimulate the immune system in different ways and stop tumor cells from growing. Cryosurgery, also known as cryotherapy, kills tumor cells by freezing them. Giving sargramostim after cryotherapy may work better in treating prostate cancer.


Description:

PRIMARY OBJECTIVES: I. Determine an unknown normal immune response (T cell and B cell) to post-cryotherapy treatment for prostate cancer. II. Detect the altered immune response (T cell and B cell) post-GM-CSF (sargramostim) response and post-cryotherapy for the prostate cancer. Patients are randomized to 1 of 2 treatment arms. ARM I (TREATMENT): Patients undergo cryotherapy on day 0 and receive sargramostim subcutaneously (SC) on days 1, 3, 5, 8, 10, and 12. ARM II (CONTROL): Patients undergo cryotherapy on day 0. After completion of study treatment, patients are followed up for 6 months.


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date December 21, 2020
Est. primary completion date December 1, 2017
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Patients diagnosed with prostate cancer that elect to undergo primary cryotherapy of the prostate - Patients who are diagnosed with clinical stage T1a -T2c prostate cancer - Gleason score sum of less than or equal to 7 - Prostate-specific antigen (PSA) < 20 ng/dl - Patient will read, understand and sign the informed consent and Health Insurance Portability and Accountability Act (HIPAA) agreement - Patients must have a life expectancy of at least one year Exclusion Criteria: - Known hypersensitivity to granulocyte macrophage colony stimulating factor (GM-CSF) or yeast - Anticipated blood donation within the next 90 days - Magnetic resonance imaging (MRI), computed tomography (CT) and bone scan evidence of metastatic prostate cancer regardless the PSA level; (the indication for which is clinically driven and at the discretion of the treating physician) - Any history of current or within the past 48 hours of acute or chronic bacterial, fungal or viral infectious disease - Documented excessive leukemic myeloid blasts in the bone marrow or peripheral blood (>= 10%) in the past 6 months - Previous organ transplant - Immunosuppression including primary, secondary, iatrogenic and idiopathic - Other serious diseases (hematological, hepatic, renal, respiratory, central nervous system, autoimmune or psychiatric) - Enrollment in other studies for any disease in the past 30 days - Diagnosis of cancer that in not considered cured, except basal cell carcinoma (BCC) of skin - Prior transurethral resection of the prostate with a large tissue defect (at the discretion of the investigator) - History of abdominoperineal resection for rectal cancer, rectal stenosis, or other major rectal pathology - Patient currently receiving lithium, steroid, chemotherapy or radiotherapy treatment - Patients with a Hemoglobin of less than 12%

Study Design


Intervention

Procedure:
cryotherapy
Undergo cryotherapy
Biological:
sargramostim
Given subcutaneously

Locations

Country Name City State
United States University of Colorado Cancer Center Aurora Colorado

Sponsors (2)

Lead Sponsor Collaborator
University of Colorado, Denver EDAP TMS S.A.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in B cell response identified by Serametrix assay A scatter plot of each cytokine and antigen level will be created for each patient by marker to observe the behavior of the markers (rising, falling, flat, or combination over time). Patient specific pre-operative levels will be used to obtain individual baseline measures from which the difference in follow-up cytokine and antigen levels will be calculated, then a simple descriptive comparison of the mean elevation in the markers' levels across cohorts will be graphed. Baseline to up to 3 months after cryotherapy
Primary Change in T cell responses identified by Intracellular cytokine assay and enzyme-linked immunospot A scatter plot of each cytokine and antigen level will be created for each patient by marker to observe the behavior of the markers (rising, falling, flat, or combination over time). Patient specific pre-operative levels will be used to obtain individual baseline measures from which the difference in follow-up cytokine and antigen levels will be calculated, then a simple descriptive comparison of the mean elevation in the markers' levels across cohorts will be graphed. Baseline to up to 3 months after cryotherapy
Secondary Change in PSA levels in serum samples Up to 6 months after cryotherapy
See also
  Status Clinical Trial Phase
Completed NCT02217709 - Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer Phase 2
Recruiting NCT03718260 - PSMA-PET Registry for Recurrent Prostate Cancer N/A
Active, not recruiting NCT01685125 - Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Phase 2
Completed NCT01054079 - Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer Phase 2
Terminated NCT00512668 - Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer Phase 1
Completed NCT00103194 - Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer Phase 2
Completed NCT00087139 - Ixabepilone in Treating Patients With Metastatic Prostate Cancer Phase 2
Recruiting NCT05304858 - Tumor Microenvironment Analysis of Prostate Cancer Metastasis
Active, not recruiting NCT01655836 - High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer Phase 1
Terminated NCT01866423 - Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Phase 2
Not yet recruiting NCT06070272 - Determining Patterns In Trial Experiences of Recurrent Prostate Cancer Patients
Completed NCT01468532 - Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Phase 1/Phase 2
Completed NCT01260688 - Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel Phase 2
Completed NCT01682941 - Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen N/A
Completed NCT01220817 - Safety and Efficacy of POMx Capsules in Men With Recurrent Prostate Cancer: An 18-Month Study Phase 2
Completed NCT00775866 - MRI-Guided Biopsy of Recurrent Prostate Cancer After Radiotherapy N/A
Completed NCT00074022 - GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors Phase 1/Phase 2
Recruiting NCT05044754 - SCAP vs HIFU for Recurrent Prostate Cancer After Radiation Therapy
Active, not recruiting NCT01923506 - Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery Phase 1
Completed NCT01808222 - FACBC for Recurrent Prostate Cancer Phase 2